BiotechTube

Mirabegron + Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intraocular Pressure

Conditions

Intraocular Pressure

Trial Timeline

Nov 1, 2010 → Feb 1, 2011

NCT ID
NCT01284309

About Mirabegron + Placebo

Mirabegron + Placebo is a phase 1 stage product being developed by Astellas Pharma for Intraocular Pressure. The current trial status is completed. This product is registered under clinical trial identifier NCT01284309. Target conditions include Intraocular Pressure.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (9)

NCT IDPhaseStatus
NCT04641975Phase 3Terminated
NCT02787083Phase 3Terminated
NCT02216214ApprovedCompleted
NCT02086188ApprovedCompleted
NCT02092181ApprovedCompleted
NCT01284309Phase 1Completed
NCT00912964Phase 3Completed
NCT00662909Phase 3Completed
NCT00410514Phase 2Completed

Competing Products

6 competing products in Intraocular Pressure

See all competitors
ProductCompanyStageHype Score
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
52
ipilimumab + Tyrosinase/gp100/MART-1 PeptidesBristol Myers SquibbPhase 2
51
OMS302 + PlaceboOmeros CorporationPhase 3
72
Part 1 OMS302 + Part 2 OMS302 + Part 2 PlaceboOmeros CorporationPhase 3
72
OMS302 + PlaceboOmeros CorporationPhase 3
72
cisplatin + sunitinib malate + tamoxifen citratePacific BiosciencesPhase 2
44

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85